<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373866</url>
  </required_header>
  <id_info>
    <org_study_id>2009_17/0927</org_study_id>
    <secondary_id>2009-A00842-55</secondary_id>
    <nct_id>NCT01373866</nct_id>
  </id_info>
  <brief_title>Multimodal MRI-guided rTMS to Treat Refractory Hallucinations</brief_title>
  <acronym>MULTIMODHAL</acronym>
  <official_title>Multimodal MRI-guided Repetitive Transcranial Magnetic Stimulation to Treat Drug-resistant Hallucinations: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from
           drug-resistant multisensory hallucinations will be tested by the implementation of a
           double-blind randomized controlled trial (RCT)

        -  This study will use a combination of different MRI modalities (fMRI and DTI) to define
           with precision rTMS brain-targets in the case of multisensory hallucinations

        -  The investigators anticipate that multimodal MRI-guided rTMS will allow a significant
           improvement in the efficacy of neuromodulation treatment of refractory hallucinations
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2010</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity and Frequency of Hallucinations</measure>
    <time_frame>Assessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12)</time_frame>
    <description>Visual Analogue Scale (Severity)/ Visual Analogue Scale (Frequency rate)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical State</measure>
    <time_frame>Assessed at baseline (t0) and longitudinally after the 10 rTMS sessions during the following month (D+15, M+1, M+3, M+6, M+12)</time_frame>
    <description>Clinical Global Improvement [CGI]/ Positive &amp; Negative Symptoms Scale [PANSS]/ Global Assessment of Functioning [GAF].
For the auditory modality: Add the Auditory Hallucinations rating Scale [AHRS] frequency scale and total score/ Add the computerized Binary Scale of Auditory Speech Hallucinations [cbSASH]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI changes</measure>
    <time_frame>Assessed at baseline (t0) and 1 month after the rTMS sessions (M+1)</time_frame>
    <description>structural MRI/ functional MRI/ Diffusion Tensor Imaging/ MR-spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hallucinations</condition>
  <condition>Schizophrenia</condition>
  <condition>Perceptual Disorders</condition>
  <arm_group>
    <arm_group_label>Multimodal MRI-guided rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional T3-P3 rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MagPro X100 repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Target defined using both fMRI during hallucinations occurence and tractography.
Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session</description>
    <arm_group_label>Multimodal MRI-guided rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MagPro X100 repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session</description>
    <arm_group_label>Conventional T3-P3 rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Right-handed Female/Male, [13-60 y.o.],

          -  Schizophrenia (DSM-IV-TR diagnosis),

          -  Drug-resistant hallucinations (Kinon &amp; Kane criteria, 1993),

          -  Unmodified antipsychotic dosage during the 30 days preceding rMTS,

          -  No anticonvulsive medication,

          -  No neurological disorder, no addictive behavior,

          -  Matched for sex, age and PANSS scores,

          -  Consent to participate to the study,

        Exclusion Criteria:

          -  Pregnancy

          -  Contraindication to MRI scan

          -  Contraindication to rTMS treatment

          -  Claustrophobia

          -  No social insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud Jardri, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lille University Medical Centre, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud Jardri, M.D., Ph.D.</last_name>
    <email>renaud.jardri@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lille University Hospital Centre</name>
      <address>
        <city>Lille</city>
        <zip>F-59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud JARDRI, M.D., Ph.D.</last_name>
      <email>renaud.jardri@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Anne Psychiatric Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion PLAZE, MD, PhD</last_name>
      <email>m.plaze@ch-sainte-anne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>Neuronavigation</keyword>
  <keyword>Functional Magnetic Resonance Imaging</keyword>
  <keyword>Diffusion Tensor Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
    <mesh_term>Perceptual Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

